PolitiKit

Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.

Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases

Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.

Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.

Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions to improve access for rare disease patients.

Implementation of the National Strategy for Drugs for Rare Diseases, and other policies or programs for rare disease medicines.

Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines.

Federally-funded public drug plans, with respect to reimbursement for rare disease medicines for federal plan beneficiaries.

Enhancement to Canada's regulatory and funding environment for new rare disease medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions to improve access for rare disease patients.

Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.

Enhancements related to intellectual property legislation, regulations and policies applicable to rare disease medicines.

Federally-funded public drug plans, with respect to reimbursement for rare disease medicines for federal plan beneficiaries.

Implementation of the National Strategy for Drugs for Rare Diseases, and other policies or programs for rare disease medicines.

Discussions on strengthening Canada’s adult immunization programs, as access to adult vaccines remains inconsistent, inequitable and underfunded throughout the country.

Discussions on the renewal of the National Immunization Strategy to bolster public vaccination programs across Canada.

Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases

Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.

Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.

Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.

Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.

Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases

Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.

Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.

Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.

Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.

Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.

Adoption of Bill S-201, An Act respecting a national framework on sickle cell disease, to discuss measures and initiatives to improve care and treatment of Canadians affected by sickle cell disease and increase public awareness of the disease.

Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.

Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases

Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.

Regulatory amendments and/or guidelines related to the Food and Drugs Act Regulations and Health Canada to implement an orphan drug regulatory framework.

Enhancement to Canada's regulatory and funding environment for new medicines, including Health Canada authorizations of medicines and framework for clinical trials, health technology assessment processes, reimbursement negotiations and funding decisions.

Innovation, Science and Economic Development Canada and Innovation Agenda, Science and Technology Strategy, or other Government policy or program initiatives to support research and development activities and attract investments in Canada, including the Biomanufacturing and Life Sciences Strategy

Federally-funded Public Drug Plans, with respect to reimbursement for drug products for federal plan beneficiaries.

Implementation of Canada's action plan for pain and federal initiatives related to pain management.

Implementation of the the Pharmacare Act and the National Strategy for Drugs for Rare Diseases Implementation of the National Strategy for Drugs for Rare Disease, and other policies or programs related to rare diseases

Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases.

Regulatory amendments and/or guidelines and/or policies related to the Food and Drugs Act and Health Canada review of drugs for rare diseases.

Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with Canada's Drug Agency and/or other pan-Canadian health organizations.

Federally-funded public drug plans, with respect to reimbursement fof medicines for federal plan beneficiaries.

Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases.

Federally-funded public drug plans, with respect to reimbursement fof medicines for federal plan beneficiaries.

Regulatory amendments and/or guidelines and/or policies related to the Food and Drugs Act and Health Canada review of drugs for rare diseases.

Canada’s Innovation and Skills Plan, led by Innovation, Science and Economic Development Canada, with respect to ensuring that the life sciences sector is a major focus of the government’s post-COVID recovery plan.

Health Canada Regulations Amending the Patented Medicines Regulations (Additional Factors and Information Reporting Requirements) (SOR/2019-298) published in the Canada Gazette Part 2 on August 21, 2019.

Engagement with federal officials regarding Innovation, Science and Economic Development Canada’s plans for the creation of new biomanufacturing capacity for Canada.

Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board

Engagement with officials regarding Health Canada’s proposed development of a strategy for drugs for rare disorders and other aspects of national pharmacare, including proposals for a Canada Drug Agency and a national formulary.

Health Canada Regulations Amending the Patented Medicines Regulations (Additional Factors and Information Reporting Requirements) (SOR/2019-298) published in the Canada Gazette Part 2 on August 21, 2019.

Canada’s Innovation and Skills Plan, led by Innovation, Science and Economic Development Canada, with respect to ensuring that the life sciences sector is a major focus of the government’s post-COVID recovery plan.

Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board

Discussions with government about support for people living with arthritis

Excise Tax Act, specifically with respect to the application of sales tax on medical cannabis.

Discussions with government officials with respect to policy and regulation of medical cannabis.

Discussion with government officials about national pharmacare (Bill C-64) and timely access to treatment for people living with arthritis.

Discussions with government about support for people living with arthritis

Advocate for increased government funding for research related to arthritis and to support patient oriented research. Government support for health charities.

Discussions with government officials with respect to policy and regulation of medical cannabis.

Discussion with government officials about national pharmacare (Bill C-64) and timely access to treatment for people living with arthritis.